NOLVADEX-D TABLET 20 mg

4.1 Therapeutic indication

NOLVADEX is indicated for the treatment of breast cancer.

4.3 Contraindications

Pregnancy: NOLVADEX must not be given during pregnancy. Premenopausal patients must be carefully examined before treatment to exclude the possibility of pregnancy (see also Pregnancy and lactation – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

NOLVADEX should not be given to patients who have experienced hypersensitivity to the product or any of its ingredients.

4.2 Posology and method of administration

Route of administration: Oral.

Adults (including elderly)

The dosage range is 20 to 40 mg daily, given either in divided doses twice daily or as a single dose once daily.

Use in children

The use of NOLVADEX is not recommended in children, as safety and efficacy have not been established (see Pharmacodynamic and Pharmacokinetics properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).